{
  "id": "5a777ab9faa1ab7d2e00000a",
  "type": "factoid",
  "question": "What is the drug target(s) for Belsomra?",
  "ideal_answer": "Belsomra is a dual orexin receptor antagonist for both the Ox1 and Ox2 receptors",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
    "http://www.ncbi.nlm.nih.gov/pubmed/25227290",
    "http://www.ncbi.nlm.nih.gov/pubmed/28012090",
    "http://www.ncbi.nlm.nih.gov/pubmed/28279667",
    "http://www.ncbi.nlm.nih.gov/pubmed/28035034",
    "http://www.ncbi.nlm.nih.gov/pubmed/28365447",
    "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
    "http://www.ncbi.nlm.nih.gov/pubmed/27825624",
    "http://www.ncbi.nlm.nih.gov/pubmed/26864332",
    "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
    "http://www.ncbi.nlm.nih.gov/pubmed/27471419"
  ],
  "snippets": [
    {
      "text": "Suvorexant (Belsomra\u00ae) is a novel sedative hypnotic drug that is prescribed to promote sleep in patients with insomnia. It is the first of a new class of drugs classified as dual orexin receptor antagonists (DORAs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dual orexin receptor antagonist suvorexant (Belsomra\u00ae) for the treatment of insomnia as a promising sign of the potential clinical utility of orexin-based therapies for the treatment of addiction",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28012090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant (Belsomra\u00ae) is a dual orexin receptor antagonist approved for the treatment of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28279667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant is a dual orexin receptor agonist and is currently approved for the treatment of insomnia in the United States and Japan",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28365447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant (Belsomra(\u00ae)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25227290",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Last, we look ahead to the next decade of the research in this area, highlighting the recent FDA approval of the dual orexin receptor antagonist suvorexant (Belsomra",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28012090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compound 80\u2009c [{(1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl}(4-methyl-[1,1'-biphenyl]-2-yl)methanone] is a potent and selective DORA that inhibits the stimulating effects of orexin peptides OXA and OXB at both Ox1 and Ox2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27390287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant is a dual orexin receptor antagonist (DORA) which is available for the treatment of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant (MK-4305, Belsomra\u00ae) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26864332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Suvorexant (Belsomra) is the first dual orexin receptor antagonist to be approved in the US and Japan and has demonstrated efficacy in decreasing time to sleep onset and increasing total sleep time. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D000068797"
  ],
  "exact_answer": "orexin recptors"
}